Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection
<b>Background/Objectives</b>: Neutropenia is a common adverse effect of oral valganciclovir (VGCV) treatment in infants with congenital cytomegalovirus infection (CCMVI), with an estimated prevalence of 20%. However, its clinical course and associated factors, including the influence of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-07-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/7/1739 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849407555322773504 |
|---|---|
| author | Aoi Kawamura Shinya Abe Keisuke Shirai Yu Masuda Yukihito Imagawa Yuki Nakata Takumi Kido Mariko Ashina Hisayuki Matsumoto Kenji Tanimura Yasumasa Kakei Takumi Imai Kandai Nozu Kazumichi Fujioka |
| author_facet | Aoi Kawamura Shinya Abe Keisuke Shirai Yu Masuda Yukihito Imagawa Yuki Nakata Takumi Kido Mariko Ashina Hisayuki Matsumoto Kenji Tanimura Yasumasa Kakei Takumi Imai Kandai Nozu Kazumichi Fujioka |
| author_sort | Aoi Kawamura |
| collection | DOAJ |
| description | <b>Background/Objectives</b>: Neutropenia is a common adverse effect of oral valganciclovir (VGCV) treatment in infants with congenital cytomegalovirus infection (CCMVI), with an estimated prevalence of 20%. However, its clinical course and associated factors, including the influence of VGCV dosage, remain inadequately characterized. <b>Methods</b>: We conducted a single-center retrospective cohort study of infants treated with VGCV for symptomatic congenital CMV infection (CCMVI) at the Kobe University Hospital between 1 April 2009 and 31 March 2017. Detailed descriptive analyses of neutropenia were performed, and factors associated with its onset were explored using univariable logistic regression analyses. <b>Results</b>: A total of 31 patients were included, and neutropenia occurred in 35% of them during the 6-week treatment period. Its occurrence was observed throughout the treatment course, with no substantial difference in incidence between the 16 mg/kg/day and 32 mg/kg/day dosing groups. Neutropenia was more likely to occur in infants with shorter gestational age. <b>Conclusions</b>: Neutropenia occurred in 35% of patients during 6 weeks of VGCV treatment, irrespective of dosage, and was more common in those with shorter gestational age. |
| format | Article |
| id | doaj-art-04db9ec9cd0f4f389a639bbc569e231b |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-04db9ec9cd0f4f389a639bbc569e231b2025-08-20T03:36:02ZengMDPI AGBiomedicines2227-90592025-07-01137173910.3390/biomedicines13071739Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus InfectionAoi Kawamura0Shinya Abe1Keisuke Shirai2Yu Masuda3Yukihito Imagawa4Yuki Nakata5Takumi Kido6Mariko Ashina7Hisayuki Matsumoto8Kenji Tanimura9Yasumasa Kakei10Takumi Imai11Kandai Nozu12Kazumichi Fujioka13Department of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Clinical Laboratory, Kobe University Hospital, Kobe 650-0017, JapanDepartment of Obstetrics and Gynecology, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanClinical and Translational Research Center, Kobe University Hospital, Kobe 650-0017, JapanClinical and Translational Research Center, Kobe University Hospital, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, JapanDepartment of Pediatrics, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan<b>Background/Objectives</b>: Neutropenia is a common adverse effect of oral valganciclovir (VGCV) treatment in infants with congenital cytomegalovirus infection (CCMVI), with an estimated prevalence of 20%. However, its clinical course and associated factors, including the influence of VGCV dosage, remain inadequately characterized. <b>Methods</b>: We conducted a single-center retrospective cohort study of infants treated with VGCV for symptomatic congenital CMV infection (CCMVI) at the Kobe University Hospital between 1 April 2009 and 31 March 2017. Detailed descriptive analyses of neutropenia were performed, and factors associated with its onset were explored using univariable logistic regression analyses. <b>Results</b>: A total of 31 patients were included, and neutropenia occurred in 35% of them during the 6-week treatment period. Its occurrence was observed throughout the treatment course, with no substantial difference in incidence between the 16 mg/kg/day and 32 mg/kg/day dosing groups. Neutropenia was more likely to occur in infants with shorter gestational age. <b>Conclusions</b>: Neutropenia occurred in 35% of patients during 6 weeks of VGCV treatment, irrespective of dosage, and was more common in those with shorter gestational age.https://www.mdpi.com/2227-9059/13/7/1739neutrophil nadirneutropeniavalganciclovircongenital cytomegalovirus infection |
| spellingShingle | Aoi Kawamura Shinya Abe Keisuke Shirai Yu Masuda Yukihito Imagawa Yuki Nakata Takumi Kido Mariko Ashina Hisayuki Matsumoto Kenji Tanimura Yasumasa Kakei Takumi Imai Kandai Nozu Kazumichi Fujioka Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection Biomedicines neutrophil nadir neutropenia valganciclovir congenital cytomegalovirus infection |
| title | Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection |
| title_full | Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection |
| title_fullStr | Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection |
| title_full_unstemmed | Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection |
| title_short | Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus Infection |
| title_sort | changes in neutrophil count during valganciclovir therapy for symptomatic congenital cytomegalovirus infection |
| topic | neutrophil nadir neutropenia valganciclovir congenital cytomegalovirus infection |
| url | https://www.mdpi.com/2227-9059/13/7/1739 |
| work_keys_str_mv | AT aoikawamura changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT shinyaabe changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT keisukeshirai changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT yumasuda changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT yukihitoimagawa changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT yukinakata changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT takumikido changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT marikoashina changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT hisayukimatsumoto changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT kenjitanimura changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT yasumasakakei changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT takumiimai changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT kandainozu changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection AT kazumichifujioka changesinneutrophilcountduringvalganciclovirtherapyforsymptomaticcongenitalcytomegalovirusinfection |